Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhoea: patient selection and reported outcomes

Cristina Saavedra, Jorge Barriuso, Mairead Mcnamara, Juan Valle, Angela Lamarca

Research output: Contribution to journalArticlepeer-review

Abstract

Neuroendocrine tumours (NETs) are rare cancers with an associated prolonged survival in some patients. A proportion of patients diagnosed with NETs will present with symptoms in keeping with carcinoid syndrome; characterised by diarrhoea, flushing and/or wheezing. This review summarises the current treatment options for carcinoid syndrome, focusing on the latest novel treatment option, telotristat ethyl. In addition, information on patient-reported outcomes and impact of carcinoid syndrome on quality of life and improvement following treatment with telotristat ethyl is reviewed. This manuscript also provides an overview of current quality of life questionnaires for patients with NETs and addresses unmet needs in this field of patient reported outcomes.
Original languageEnglish
JournalCancer Management and Research
Early online date8 Aug 2019
DOIs
Publication statusPublished - 2019

Keywords

  • telotristat ethyl
  • carcinoid syndrome
  • NET
  • diarrhoea

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Fingerprint

Dive into the research topics of 'Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhoea: patient selection and reported outcomes'. Together they form a unique fingerprint.

Cite this